Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amicus Therapeutics reports robust revenue growth and eyes AT-GAA launch

Amicus Therapeutics showcased strong performance and growth prospects for Galafold and AT-GAA therapy.
The company aims for non-GAAP profitability in 2023, focusing on key strategic priorities and market expansion.
Challenges include profitability targets, regulatory approvals, and managing production costs for new therapies.
Opportunities lie in the anticipated AT-GAA launch, geographic market expansion, and continued revenue growth.

Amicus Therapeutics reports robust Q1 performance and eyes AT-GAA FDA approval

Amicus Therapeutics delivered strong Q1 results, focusing on revenue growth, regulatory milestones, and financial stability. The company's strengths lie in Galafold sales growth, positive patient outcomes with AT-GAA, and market opportunities in Pompe disease treatment. Challenges include scaling up patient numbers and transitioning manufacturing facilities, while opportunities exist in market expansion and physician engagement.

Amicus Therapeutics excels in Q2, eyes global expansion and profitability

Amicus Therapeutics demonstrates strong financial growth, focusing on expanding market presence and achieving non-GAAP profitability. The company's performance with Galafold and progress on regulatory filings position it well for future success, despite facing challenges in patient transitions and leadership changes.

Amicus Therapeutics reports robust Q3 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q3 2023, with revenue growth and profitability on track, supported by strategic investments and market expansion efforts.
The company's focus on patient-centric approaches, physician engagement, and global market penetration positions it well for future growth and success.
While facing challenges in gene therapy programs and revenue dynamics, Amicus is actively addressing these issues and leveraging opportunities in expanding markets and innovative therapies.
Overall, Amicus Therapeutics remains well-positioned in the biopharmaceutical industry, with a strong foundation for continued growth and impact in treating rare diseases.

Amicus Therapeutics reports strong Q4 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q4 2023, aiming for sustained growth and profitability in 2024 through strategic priorities and successful product launches.
The company faces challenges in forecasting seasonal trends and expanding payer coverage, yet opportunities lie in maximizing patient therapy, leveraging AI advancements, and broadening market reach.
With a focus on rare disease treatments and market penetration, Amicus is poised for growth and intervention strategies to address patient variability and drive revenue in 2024.

Amicus Therapeutics reports strong Q1 performance and growth opportunities

Amicus Therapeutics delivered strong Q1 2024 results, driven by Galafold's performance and a focus on expanding patient numbers for Pombiliti and Opfolda.
While facing challenges such as increased operating expenses and potential manufacturing issues, the company remains confident in its growth trajectory and supply capabilities.
Opportunities lie in revenue expansion, leveraging positive feedback for Pombiliti and Opfolda, and enhancing real-world evidence generation through registries.
Efforts to streamline treatment processes and establish new standards of care position Amicus for continued growth and impact in the rare disease space.

Amicus Therapeutics (FOLD) reports robust Q3 earnings and growth strategies

Amicus Therapeutics (FOLD) delivered strong financial performance in Q3 2024, driven by robust Galafold revenue and strategic focus on patient access.
While facing competitive pressures and regulatory challenges, the company aims to sustain growth through pipeline development and expense management.
Raising financial guidance and exploring accelerated approval opportunities position Amicus for continued success in the genetic medicine market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.

Amicus (FOLD) Filings for AT-GAA in Pompe Disease Accepted by EMA

PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) for AT-GAA, the Company's investigational two-component therapy for the treatment of Pompe disease. Validation of the application confirms the submission is accepted, and the EMA's centralized procedure with Committee for Medicinal Products for Human Use (CHMP)'s assessment begins.

European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease

PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T.

Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021.

Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism

Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need

The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease

PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 8:00 a.m. E.T.

Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

Amicus (FOLD) misses both Q3 earnings and revenue estimates. Resultantly, the stock price falls.

Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss

Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2021 Results - Earnings Call Transcript

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -5.56% and -2.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates

3Q21 Total Galafold ® Revenue of $79.5M – an 18% increase over 3Q20

Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates

PHILADELPHIA, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2021.

Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Amicus Therapeutics (FOLD) Report Negative Q3 Earnings? What You Should Know

The consensus price target hints at a 77.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Amicus Therapeutics (FOLD) Climb 77% to Reach the Level Wall Street Analysts Expect?

It has been a rocky year for Amicus Therapeutics, Inc. (NASDAQ:FOLD), after the stock suffered a dramatic bear gap back in February that it hasn't even come close to recovering from.

Pharma Stock Looks Poised for a Pre-Earnings Pop

The average of price targets set by Wall Street analysts indicates a potential upside of 59.3% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 59% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know

Amicus Therapeutics announced the formation of Caritas Therapeutics, consisting of Amicus' gene therapy portfolio.

Amicus Therapeutics Carves Out Gene Therapy Portfolio, Reduces Upside Optionality

New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Amicus Therapeutics, Inc. (NASDAQ: FOLD) ("Amicus" or the "Company") stock prior to September 29, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Amicus with ARYA Sciences Acquisition Corp IV. Upon t

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Amicus Therapeutics, Inc. with ARYA Sciences Acquisition Corp IV

Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.

Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA

Shares of Amicus Therapeutics Inc. FOLD, -5.11% were up 5.6% in premarket trading on Thursday, the day after the company announced a deal to sell its gene therapy business to ARYA Sciences Acquisition Corp IV ARYD, +0.90% , a special purpose acquisition company sponsored by Perceptive Advisors. Amicus will have a 36% stake in the new company, which will be called Caritas Therapeutics Inc. It will retain commercialization rights to the Fabry and Pompe gene therapy programs.

Amicus stock is up 5%, the day after announcing plans to sell its gene therapy business

Amicus Therapeutics, Inc. (FOLD) on Formation of Caritas Therapeutics Conference Call (Transcript)

Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic medicine company Caritas Therapeutics Inc. ARYA Sciences Acquisition Corp IV is SPAC, sponsored by Perceptive Advisors.

Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business

The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat for AT-GAA. Also Read:   Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents

Why Are Amicus Therapeutics Shares Trading Higher Today?

FDA Sets PDUFA Target Action Date of May 29, 2022 for the New Drug Application and  July 29, 2022 for the Biologics License Application

U.S. FDA Accepts Filings for Amicus' AT-GAA for the Treatment of Pompe Disease

Business Combination of Amicus Gene Therapy Business with ARYA IV to Result  in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company  with Expected ~$400M in Initial Funding

Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”

PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September:

News for Amicus Therapeutics Stock (FOLD)